Appropriate but not cost effective ceftazidime use in a university hospital.
An evaluation of ceftazidime use at a university hospital was performed. Drug utilization evaluations usually categorize therapies as appropriate or inappropriate, with the inappropriate category including all regimens which are not cost effective. This may be misleading since therapy which is therapeutically appropriate may be labeled as inappropriate. Therefore, ceftazidime use was classified as appropriate, appropriate but not cost effective, or inappropriate. Clinical pharmacists reviewed the charts of 72 patients over a 1 month period. Courses of therapy were first categorized as empiric or definitive and as appropriate or inappropriate. Those that were appropriate were further analyzed to determine cost effectiveness. When a more cost effective regimen was available, the difference in cost was calculated; the cost of inappropriate therapy was compared to that of an appropriate alternative regimen. Ceftazidime use was appropriate and cost effective in 22% of courses, appropriate but not cost effective in 66%, and inappropriate in 11%. Annual savings of up to $72,000 could be realized in our 550 bed hospital by intervention into appropriate but not cost effective therapy and inappropriate therapy.
D002442:Ceftazidime / Q000627:therapeutic use*; D002985:Clinical Protocols; D003362:Cost-Benefit Analysis / Q000706:statistics & numerical data*; D004363:Drug Utilization / Q000191:economics*; D005069:Evaluation Studies as Topic; D006746:Hospital Bed Capacity, 500 and over; D006784:Hospitals, Teaching / Q000191:economics*; D006785:Hospitals, University / Q000191:economics*; D006801:Humans; D008824:Michigan; D010607:Pharmacy Service, Hospital